Survodutide

Research Phase

Survodutide (BI 456906)

Aliases
BI 456906
Administration
Subcutaneous injection

How it works

  1. Activates the GLP-1 receptor to suppress appetite and slow digestion, similar to semaglutide.

    Most weight-loss peptides work by making you less hungry. Survodutide does that too, but it also directly tells your body to burn more calories at rest, which is the added glucagon-receptor effect.

  2. Simultaneously activates the glucagon receptor, which increases energy expenditure and liver fat metabolism — an effect single-pathway GLP-1 drugs don't have.

    This dual action is also why it's being studied for a liver condition (MASH) specifically, since the glucagon-receptor pathway affects how the liver processes fat.

Result

Trial data suggests substantial weight loss driven by both reduced appetite and increased calorie burning, a combined mechanism distinct from single-pathway GLP-1 drugs — though it remains investigational and is not yet available outside clinical trials.